Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caudal-epidural versus trigger point corticosteroid injection for myofascial chronic back pain
IRCT20241017063397N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ropivacaine in chronic myofascial pain (CMP) and chronic back pain (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Sleep quality, Stress and 2 more. Started Dec 2024; status: completed.
02
Drugs
ropivacaine
03
Conditions
chronic myofascial pain (CMP)chronic back pain
Beyond the preview
Go deeper on IRCT20241017063397N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241017063397N1.